1197810-60-8
Chemical Structure
GLP-1 moiety from Dulaglutide
Synonym(s): [Gly8,36,Glu22]-GLP-1 (7-37)
- CAS No.: 1197810-60-8
- Formula:C149H221N37O49
- Molecular Weight:3314.62
SMILES: O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(NCC(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CNC=N6)N
Biological Activity: GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GLP-1 moiety from Dulaglutide | 99.60% | GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Anthony Celeste, et al. Anti-pcsk9-glp-1 fusions and methods for use. United States. US 20160369010 A1. 2015-02-20.
- [2]. Xi L, et al. Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice. Peptides. 2025 Mar;185:171366. [Content Brief]
- [3]. Wang R, et al. Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes. ACS Omega. 2021 Mar 18;6(12):8271-8278. doi: 10.1021/acsomega.0c06326. Erratum in: ACS Omega. 2022 May 26;7(22):19040. [Content Brief]
Keywords